Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2022-10-12 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PTX 7 pages 28.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. There is no financial performance data, management discussion, or regulatory certification. The content focuses on the issuance and quotation of new securities, which aligns with announcements related to capital changes or share issues. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a substantive filing about share issuance.
2022-10-12 English
Change of Director's Interest Notices x2 6 pages 331.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including the number of shares and options held before and after the change, the nature of the change, and the consideration paid. The document is a formal notification of personal share transactions by company directors. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 9437 characters, which is sufficient to contain detailed transaction information rather than a brief announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2022-10-11 English
Placement Results 3 pages 707.2KB
Capital/Financing Update Classification · 95% confidence The document is an announcement about a capital raising event by Prescient Therapeutics, specifically a Top-Up Placement raising $2.5 million, with details on the use of proceeds and share allotment dates. It discusses the company's business and pipeline but does not contain financial statements or detailed financial performance data. The document is not a full financial report, earnings release, or regulatory filing of financial results. It is clearly an update on financing activity, including share issuance and capital raising. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (9907 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2022-10-10 English
Proposed issue of securities - PTX 5 pages 28.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Prescient Therapeutics Limited. It details the number of securities to be issued, the issue price, the proposed issue date, and other related information such as fees and conditions. The content focuses on a placement or other type of issue of shares, which is a capital raising activity. There are no financial statements or detailed financial performance data present, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a report but an announcement of a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-10-10 English
Application for quotation of securities - PTX 7 pages 28.5KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the application for quotation of securities issued by Prescient Therapeutics Limited. It includes information about the number and type of securities to be quoted, issue dates, and issued capital following quotation. The document references Appendix 3B filings, which are related to securities issuance and quotation on the ASX. There is no financial performance data, management discussion, or audit information. The document is an announcement related to the quotation of securities rather than a financial report or detailed investor presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-10-10 English
Trading Halt 2 pages 883.7KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement regarding a trading halt requested by Prescient Therapeutics Limited pending an upcoming announcement about a placement. It references ASX Listing Rule 17.1 and states the halt is to manage continuous disclosure obligations. The document does not contain financial data, detailed report content, or results but is an announcement about a trading halt related to a capital raising event. Therefore, it is an update on financing activities but is not the actual financing report or placement announcement itself. Given the nature of the document as a trading halt notice pending a capital raising announcement, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear context and content.
2022-10-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.